Table 5.

Subsequent treatment for disease progression after T790M test results

Treatment	n (%)
Positive (n = 61)
Osimertinib	55 (90.2)
Osimertinib + chemotherapy (CBDCA + PEM)	1 (1.6)
First-generation EGFR TKI	1 (1.6)
Chemotherapy (CDDP + PEM + BEV)	1 (1.6)
Investigational drug	1 (1.6)
Best supportive care	2 (3.3)
Negative (n = 138)
First-/second-generation EGFR TKI	70 (50.7)
Chemotherapy	43 (31.2)
EGFR TKI + BEV	3 (2.2)
EGFR TKI + other	1 (0.7)
Immune checkpoint inhibitor	3 (2.2)
Osimertinib	1 (0.7)
Best supportive care	11 (8.0)
Missing	6 (4.3)
No sample collected for T790M test (n = 31)
First-/second-generation EGFR TKI	16 (51.6)
Chemotherapy	6 (19.4)
First-generation EGFR TKI + BEV	2 (6.5)
Osimertinib†	2 (6.5)
Radiation therapy	1 (3.2)
Best supportive care	3 (9.7)
None (due to death)	1 (3.2)

BEV bevacizumab, CBDCA carboplatin, CDDP cisplatin, EGFR epidermal growth factor receptor, PEM pemetrexed, TKI tyrosine kinase inhibitor

^†Patients detected positive for T790M mutation before enrollment